Live Stream: Clean-Up on IL-23: Integrating the Science of Inflammatory Targets into Treatment Decision-making in IBD

Faculty

Jessica R. Allegretti, MD, MPH, FACG, AGAF
Director, Crohn’s and Colitis Center
Director of Clinical Research
Director, Fecal Microbiota Transplant Program
Division of Gastroenterology, Hepatology and Endoscopy
Brigham and Women's Hospital
Associate Professor of Medicine, Harvard Medical School
Boston, MA
Jessica R. Allegretti, MD, MPH, FACG, AGAF

Jessica R. Allegretti, MD, MPH is an Associate Professor of Medicine at Harvard Medical School in the Division of Gastroenterology, Hepatology and Endoscopy, and is the Medical Director of the Crohn’s and Colitis Center at Brigham and Women’s Hospital, where she built and leads the Clinical Trials Program and Fecal Microbiota Transplant Program. Dr. Allegretti graduated from The Miller School of Medicine at the University of Miami in Miami, Florida, trained in internal medicine at Massachusetts’s General Hospital in Boston, Massachusetts, and completed her gastroenterology fellowship training at Brigham and Women’s Hospital before joining faculty there. She later went on to receive a Master of Public Health degree from the Harvard School of Public Health in Boston, Massachusetts.

Dr. Allegretti is a physician-scientist dedicated to discovering and developing innovative microbiome therapeutics and novel treatments for inflammatory bowel disease (IBD). Her research focus is on the mechanism recurrent C.difficile infection (CDI) and the intersection of CDI and IBD. She has authored more than 100 peer-reviewed publications. She has received funding from the National Institutes of Health (NIH), the American College of Gastroenterology and the Crohn’s and Colitis Foundation. Dr. Allegretti has been featured on Home Box Office (HBO), British Broadcasting Corporation (BBC), Netflix, the New York Times and numerous other media outlets. In 2020, Dr. Allegretti received the Sherman Emerging Leader Prize for Excellence in Crohn’s and Colitis (IBD).

David T. Rubin, MD, FACG, AGAF, FACP, FASGE, FRCP
Joseph B. Kirsner Professor of Medicine
Chief, Section of Gastroenterology, Hepatology and Nutrition
Director, Inflammatory Bowel Disease Center
University of Chicago Medicine
Chicago, IL
David T. Rubin, MD, FACG, AGAF, FACP, FASGE, FRCP

David T. Rubin, MD, FACG, AGAF, FACP, FASGE, FRCP (Edinburgh) is the Joseph B. Kirsner Professor of Medicine, a Professor of Pathology, Chief of the Section of Gastroenterology, Hepatology and Nutrition, and Director of the Inflammatory Bowel Disease (IBD) Center at the University of Chicago Medicine in Chicago, Illinois. Dr. Rubin earned a medical degree with honors at the University of Chicago Pritzker School of Medicine in Chicago, Illinois and completed his residency in internal medicine and fellowships in gastroenterology and clinical medical ethics at the University of Chicago in Chicago, Illinois, where he served as Chief Resident and Chief Fellow. He also serves as Associate Faculty at the MacLean Center for Clinical Medical Ethics, Associate Investigator at the University of Chicago Comprehensive Cancer Center, and is a member of the University of Chicago Committee on Clinical Pharmacology and Pharmacogenomics. He is the chair of the National Scientific Advisory Committee of the Crohn’s & Colitis Foundation, where he also serves as a Board of Trustees member. Dr. Rubin is the deputy chair of the Executive Committee of the International Organization for the Study of Inflammatory Bowel Disease. Prior to these appointments, he served as the Director of the Fellowship in Gastroenterology, Hepatology and Nutrition at the University of Chicago for 11 years. In 2018, Dr. Rubin completed the Harvard T.H. Chan School of Public Health Leadership Development Course for Physicians.

Dr. Rubin is a Fellow of the American Gastroenterological Association (AGA), the American College of Gastroenterology (ACG), the American Society for Gastrointestinal Endoscopy (ASGE), the American College of Physicians (ACP), and the Royal College of Physicians (Edinburgh). He is on the Board of Trustees for the ACG. Among numerous awards and honors, Dr. Rubin was chosen by his peers as a member of Best Doctors (recognized for superior clinical ability) and America’s Top Physicians (gastroenterology). Additionally, he twice received the ACG’s Governor’s Award of Excellence in Clinical Research (2003 and 2013), and the UChicago Postgraduate Teaching Award in recognition of significant contributions for fellowship education (2006). In 2012, he received the Crohn’s & Colitis Foundation’s Rosenthal Award, a national leadership award bestowed upon a volunteer who has contributed in an indisputable way to the quality of life of patients and families. He has previously served as an Associate Editor of the journal Gastroenterology and Editor-in-Chief of the ACG On-Line Education Universe. In 2020, Dr. Rubin received the Sherman Prize for Excellence in Crohn’s and Colitis.

Dr. Rubin is an editor of a best-selling book Curbside Consultation in IBD, now in its 3rd edition, was an associate editor of the 11th edition and is senior editor of the upcoming 12th edition of Sleisenger and Fordtran’s Gastrointestinal and Liver Disease, and an author or coauthor of over 500 articles on treatment and management of IBD, cancer in IBD and novel paradigms, as well as the first author of the 2019 ACG Guidelines for ulcerative colitis. His current research is in the area of novel approaches to monitoring of IBD (wearables and point of care intestinal ultrasound), prevention of progressive complications from uncontrolled inflammation, and a variety of collaborative and translational studies related to the causes of IBD and its complications. His H index is 74. He is also a featured media contact for issues related to IBD, appearing on satellite radio, television, print media and maintains a popular and verified twitter feed @IBDMD with over 20,000 followers.

Statement of Need

Recently, interleukin (IL)-23 and the inflammatory IL-23/T-helper (Th)-17 axis have been identified as central drivers of inflammation related to inflammatory bowel disease (IBD). Science in the field of cytokine-targeting therapies, specifically in the field of IL-23 P19 targeting agents, is evolving rapidly, with the first approval in the class occurring in 2022 and several other agents in late-stage development. While all agents within the anti-IL-23 class will have the ability to bind to and neutralize IL-23 via binding to the P19 domain as an essential function, structural differences in the monoclonal antibody Fc fragment result in each agent having an overall unique clinical profile.

This CME Outfitters symposium at the Crohn’s & Colitis Congress (CCC) 2024, entitled Clean-Up on IL-23: Integrating the Science of Inflammatory Targets into Treatment Decision-making in IBD, will feature an expert panel discussion on the science behind cytokine-targeting therapies and will utilize animated 3-D models to discuss therapeutic mechanisms of action (MOAs) of emerging agents, clinical distinctions between therapies, and individualizing treatments for lasting outcomes for patients with IBD.

Learning Objectives

  • Assess the role of various pro-inflammatory cytokines to inflammation in the pathogenesis of IBD
  • Classify the role of the IL-23 and Th17 pathway in IBD pathogenesis
  • Evaluate the potential clinical implications of CD64 receptor binding by anti-IL-23 mAbs in the treatment of IBD

Financial Support

Supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Target Audience

Gastroenterologists, gastroenterology fellows, physician associates (PAs), nurse practitioners (NPs), nurses and pharmacists

Credit Information

Jointly Accredited Provider

In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Interprofessional (IPCE) 1.5

This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) Credit for learning and change.

Physicians (ACCME) 1.5 LIVE

CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. CME Outfitters, LLC, designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses (ANCC) 1.5

This activity is designated for 1.5 contact hours.

Note for California Nurses

This continuing nursing education activity was approved by the California Board of Registered Nursing. CME Outfitters, LLC’s provider number is CEP15510.

Pharmacists (ACPE) 1.5

This application-based activity is approved for 1.5 contact hours (0.15 CEUs) of continuing pharmacy credit.
Activity UAN: JA0007185-0000-24-002-L01-P

PAs (AAPA) 1.5

CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until expiration date listed above. PAs should only claim credit commensurate with the extent of their participation.

ABIM MOC 1.5

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.50 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process.

Dr. Allegretti reports the following financial relationships:

Consultant: Abbvie Inc.; Adiso Therapeutics; Bristol Myers Squibb Company; Ferring Pharmaceuticals; Finch Therapeutics; GSK; Iterative Scopes; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc..; Pfizer Inc.; Roivant Sciences; and Seres Therapeutics

Research Support: Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; and Pfizer Inc.

Speakers Bureau: Abbvie Inc.; Bristol Myers Squibb Company; and Janssen Pharmaceuticals, Inc.

Dr. Rubin reports the following financial relationships:

Consultant: AbbVie Inc. ; Alimentiv Inc.; AltruBio; Amgen Inc.; Avalo Therapeutics, Inc.; Bristol Myers Squibb Company; BUHLMANN Diagnostics Corporation; ClostraBio; Connect BioPharma; Datos Health; EcoR1 Capital; Evinature;; Ferring Pharmaceuticals; Image Analysis Group (IAG); Iterative Health; Janssen Pharmaceuticals, Inc.; Lilly; Menten AI; Odyssey Therapeutics; Pfizer Inc.; Prometheus Biosciences; Reistone Biopharma; NeuroLogica Corp.; Sangamo Therapeutics; Shanghai Pharmaceuticals; Biotherapeutics, Inc.; Takeda Pharmaceuticals U.S.A., Inc.; Target RWE; Tissium; and Trellus Health Inc.

Grants: Takeda Pharmaceuticals U.S.A., Inc.

Stock Shareholder (ownership interest): Iterative Health (options available, none purchased); Datos Health (nonstatutory stock options); and AltruBio (options available, none purchased)

Disclosures were obtained from the following peer reviewers and CME Outfitters, LLC, staff, with no disclosures to report:

  • Diane M. Bruessow, MPAS, PA-C, DFAAPA (peer reviewer)
  • Jeffrey Helfand, DO (peer reviewer)
  • Karla E. Crews, MSN, RN (peer reviewer)
  • Mary Gleason, PhD (planning committee)
  • Kasey Brandt, PharmD (planning committee)
  • Susan H. Yarbrough, CHCP (planning committee)
  • Sandra Caballero, PharmD (planning committee)
  • Sharon Tordoff

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Obtaining Credit

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page.

Questions about this activity?

Call us at 877.CME.PROS (877.263.7767).

MMS-135-012624-69

Live Stream: Clean-Up on IL-23: Integrating the Science of Inflammatory Targets into Treatment Decision-making in IBD
Event Date: 01/26/2024 at 3:30 pm EST